News

Cleanspark: Market Insights from Whales and Expert Opinions

Cleanspark: Market Insights from Whales and Expert Opinions

Whale Activity in Cleanspark's Stock Options

Recently, investors with significant capital, often referred to as 'whales,' have shown a notably bullish outlook on Cleanspark. These large-scale trades indicate a growing confidence in the company's stock performance.

Examining the options trading history for Cleanspark (CLSK), we identified a total of 8 trades in recent weeks. Among these trades, approximately 50% emerged with bullish sentiment, while 25% leaned bearish.

Breakdown of Investment Trends

From the analyzed trades, there were 2 put options, cumulatively amounting to $149,147, contrasted with 6 call options that totaled $244,975. This significant disparity in call vs. put options demonstrates a stronger inclination towards optimistic market movement.

Exploring the Predicted Price Range

By evaluating the Volume and Open Interest associated with these contracts, it is evident that whales have earmarked a price target for Cleanspark, ranging from $11.0 to $37.0 over the past three months. This range provides an intriguing insight into the expectations surrounding the stock's next moves.

Understanding Volume and Open Interest

Monitoring both volume and open interest can be imperative when trading options, as these metrics effectively reveal liquidity and the prevailing interest level for a stock. For Cleanspark's options over 30 days, we can trace the activity reflecting traders' dynamic engagements.

Cleanspark's Recent Option Activity

The option activity around Cleanspark has been telling, as various trades highlight differing sentiments among investors. A recent influx of options trading has sparked interest, with significant quantities of call options being placed.

Highlighted Option Trades

Here are some of the notable options trades observed for Cleanspark:

  • Trade 1: CLSK PUTs - A sweep bullish option expiring 11/01/24, with a total trade value of $82,400.
  • Trade 2: CLSK CALLs - A neutral trade averaging $69,000, expiring on 07/18/25.
  • Trade 3: CLSK PUTs - Another bullish sweep option, also expiring on 11/01/24, priced at $66,700.
  • Trade 4: CLSK CALLs - A bearish trade of $40,300 that will expire on 10/25/24.
  • Trade 5: CLSK CALLs - A second bullish trade scheduled to expire on 10/25/24, with a reported value of $38,000.

About Cleanspark

Cleanspark Inc is recognized in the bitcoin mining sector, leveraging its wholly-owned subsidiaries to operate efficiently within this digital domain. Their entrance into this market was facilitated through an acquisition, strategically positioning itself as a significant player in the fast-evolving cryptocurrency industry.

Current Performance Overview

Currently trading at $12.25, CLSK's trading volume reached 11,404,268, reflecting a decline of -3.47%. These statistics convey that while the stock faces some pressure, the overall interest remains high.

Expert Insights on Cleanspark

In the last month, analysts have weighed in on Cleanspark, revealing an average target price near $23.33. This suggests a favorable outlook, despite fluctuating predictions. For instance, analysts from different firms have expressed varied recommendations, adjusting their price targets based on recent market activity.

Conclusion

Although options trading carries its set of risks, the potential for profitable returns is evident. Successful traders affect these opportunities through constant learning, strategic adjustments, and by staying aligned with market movements. Staying engaged with the latest options activity surrounding Cleanspark might offer valuable insights into future stock behavior.

Frequently Asked Questions

What is Cleanspark known for?

Cleanspark is primarily engaged in bitcoin mining, utilizing its subsidiaries to operate within this sector efficiently.

What recent trend has been observed among whales regarding Cleanspark?

Whales have been increasingly bullish on Cleanspark, with the majority of recent large trades being oriented towards calls.

What is the predicted price range for Cleanspark?

The predicted price range for Cleanspark's stock over the last three months is between $11.0 and $37.0.

How does the trading volume reflect on Cleanspark's stock?

The current trading volume of 11,404,268 indicates substantial market interest, despite a slight decrease in stock price.

What do analysts say about Cleanspark's future?

Analysts have varied opinions, but the average target price suggests a positive outlook, aiming towards $23.33.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Pacira BioSciences Faces Shareholder Revolt in M&A Deal

Updated Category News Views 4

A New Storm Brews Over Pacira's Sale to Viatris They say where there's smoke, there's fire, and it looks like Pacira BioSciences, Inc. (NASDAQ: PCRX) is running right into a bonfire thanks to their upcoming sale to Viatris Inc. On the face of it, shareholders are looking at a tidy $36.50 in cash per share, but not everyone's buying the deal as fair. Enter lawman Juan...

Continue Reading
Celltrion Unveils New Data on Infliximab: ACG 2026 Insight

Updated Category News Views 26

First Impressions: Celltrion's Latest Revelation Alright, let's jump straight into it. Celltrion USA is flaunting its latest findings on ZYMFENTRA® (infliximab-dyyb) for Crohn's disease and ulcerative colitis right at the American College of Gastroenterology's (ACG) grand event in 2026. If you've been watching the healthcare sector, this is significant news. It's got all...

Continue Reading
Duolingo Faces Lawsuit Over Alleged Investor Missteps

Updated Category News Views 34

Fasten your seatbelts, folks. We're diving into a legal tussle that could shake things up for Duolingo, Inc. (NASDAQ: DUOL). Investors who plunged into Duolingo shares between May 2, 2025, and February 26, 2026, might be feeling the heat now. They ought to brace for a class-action lawsuit frenzy with fingers pointed at Duolingo for allegedly pulling wool over investors'...

Continue Reading
2026 Community Impact Week: Slam Dunk for Community Unity

Updated Category News Views 21

Alright, if you're looking for a story that gives you those warm fuzzy feelings while wrapping you in a big sports hug, here it is. Imagine this: you've got basketball legends, world-class athletes, and a corporate heavyweight, all huddling up to make a community impact that's more than just warm air. Hoops, Hope, and High Fives The NBA Cares x Sands Cares Community...

Continue Reading
AbbVie's SKYRIZI and RINVOQ Highlight IBD Control Advances

Updated Category News Views 26

A Deeper Look Into AbbVie's Latest Data Let's cut straight to the science, folks. At the recent American College of Gastroenterology 2026 Annual Scientific Meeting, AbbVie pulled the curtain on 22 fresh scientific abstracts that are really shaking things up in the field of inflammatory bowel disease (IBD) treatment. Data from the Phase 3 AFFIRM study shined especially...

Continue Reading
Sebela Pharma's Tegoprazan Posts Strong Phase 3 Data

Updated Category News Views 19

Spotlight on Tegoprazan: A New Player on the GERD Field Sometimes, a pharma company turns heads with data that speaks for itself. This time, Sebela Pharmaceuticals is doing just that with Tegoprazan's phase 3 results, shining a light on an area overlooked for too long: non-erosive reflux disease (NERD). Showing promise in its latest trials, Tegoprazan is muscling into the...

Continue Reading
LEGO Mashes Star Wars and Marvel for Fans' Delight

Updated Category News Views 28

A New Chapter in LEGO's Story Well, well, what do we have here? LEGO's throwing down the gauntlet. For the first time, they're asking fans to merge two colossal universes: Star Wars and Marvel. Talk about a brains-and-bricks bonanza! Announced at New York Comic Con with some star power from Kevin Smith, this LEGO Ideas challenge opens doors for fan creativity that might...

Continue Reading

Top 5 Most Recently Viewed Articles

FTI Consulting Expands Tax Advisory Team with New Experts

Updated Category News Views 199

FTI Consulting Strengthens Tax Advisory Team FTI Consulting, Inc. (NYSE: FCN) has announced the strategic enhancement of its Tax Advisory team within the EMEA region through the recruitment of two highly experienced professionals. This move reflects the company's commitment to providing top-tier advisory services amidst the complexities of the global tax environment. New...

Continue Reading
Cingulate Inc. Unveils Q1 Financial Highlights and Future Plans

Updated Category News Views 148

Cingulate Inc. Reports First Quarter Financial Results Cingulate Inc. (NASDAQ: CING), a biopharmaceutical entity known for its innovative Precision Timed Release™ (PTR™) drug delivery technology, has recently unveiled its financial results for the first quarter. The report sheds light on several important developments concerning their lead assets for ADHD and anxiety....

Continue Reading
Innovative Partnership Propels Sen-Jam Pharmaceutical's Future

Updated Category News Views 106

Strategic Partnership to Enhance Phase 3 Trial for SJP-001 In a significant move, Sen-Jam Pharmaceutical has announced a promising partnership with TASK Clinical, a renowned global contract research organization (CRO), aimed at funding two-thirds of the upcoming Phase 3 clinical trial for its lead candidate, SJP-001. This equity-backed collaboration is not only innovative...

Continue Reading
Exploring the Future of Solar Energy: Insights from EnergySage

Updated Category News Views 231

EnergySage's Solar & Storage Marketplace Report Highlights EnergySage, a trusted name in solar market analysis, has released its latest report, which delves into the current dynamics of the solar and storage marketplace. This comprehensive analysis examines trends that are influencing the future of the industry, particularly in light of recent policy shifts. Residential...

Continue Reading
Investors' Rights: Explore Possible Violations for SCS, HLVX and Others

Updated Category News Views 166

Investigation into Potential Shareholder Violations Halper Sadeh LLC, a well-known law firm advocating for investor rights, is currently investigating several companies due to potential breaches of federal securities laws and fiduciary duties to their shareholders. Steelcase Inc. (SCS) Steelcase Inc. is reportedly undergoing a transaction involving the sale to HNI...

Continue Reading